GlassScriptPhysician profile
Kevin Myrie
NPI 1316193162
$14,402.69
in general payments reported to CMS, 2019-2025
38 companies · $3,057 in 2025
The $3,057 reported for 2025 was more than what 92% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,244 · 2020: $1,017 · 2021: $1,022 · 2022: $2,232 · 2023: $2,576 · 2024: $2,255 · 2025: $3,057.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,786 · Education: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,786.24 |
| Education | $101.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,135.61 | 2019-2025 | Farxiga, Lokelma, Saphnelo |
| Travere Therapeutics, INC. | $1,340.49 | 2019-2025 | Filspari |
| Bayer Healthcare Pharmaceuticals INC. | $1,124.42 | 2021-2025 | |
| Fresenius USA Marketing, INC. | $1,096.84 | 2019-2025 | Velphoro, Velphoro, Korsuva |
| Opko Pharmaceuticals, LLC | $988.90 | 2019-2025 | Rayaldee |
| Vifor Pharma, INC. | $880.91 | 2019-2025 | Veltassa, Korsuva |
| Mallinckrodt Hospital Products INC. | $787.19 | 2020-2025 | Acthar, Terlivaz |
| Ardelyx, INC. | $651.17 | 2024-2025 | Ibsrela, Xphozah 30 Mg |
| Otsuka America Pharmaceutical, INC. | $611.43 | 2019-2025 | Jynarque |
| Calliditas Therapeutics US INC. | $601.24 | 2022-2025 | Tarpeyo |
| Mallinckrodt Enterprises LLC | $526.37 | 2019 | |
| Ani Pharmaceuticals, INC. | $478.01 | 2022-2025 | Purified Cortrophin Gel |
| Amgen INC. | $449.38 | 2019-2025 | Tavneos, Krystexxa |
| Alexion Pharmaceuticals, INC. | $315.11 | 2019-2025 | Ultomiris |
| Novo Nordisk INC | $248.71 | 2023-2025 | Ozempic, Rivfloza, Rybelsus |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Myrie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.